Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACRSNASDAQ:ALPNNASDAQ:DMAC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.22$1.22$0.59▼$11.12$86.54M0.221.51 million shs636,944 shsALPNAlpine Immune Sciences$64.550.0%$41.49$6.71▼$64.70$4.23B1.141.94 million shs3.10 million shsDMACDiaMedica Therapeutics$2.42-3.6%$2.81$1.50▼$4.75$91.86M1.6941,772 shs5,238 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-1.61%+0.83%+6.09%-4.69%-86.67%ALPNAlpine Immune Sciences+0.05%+0.25%+64.16%+231.52%+801.96%DMACDiaMedica Therapeutics+5.02%+5.02%-8.73%-2.71%+45.93%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics1.4621 of 5 stars3.13.00.00.00.01.71.3ALPNAlpine Immune Sciences1.4502 of 5 stars2.13.00.00.02.84.20.0DMACDiaMedica Therapeutics1.1903 of 5 stars3.53.00.00.01.90.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics2.14Hold$22.251,723.77% UpsideALPNAlpine Immune Sciences2.27Hold$50.33-22.02% DownsideDMACDiaMedica Therapeutics3.00Buy$7.00189.26% UpsideCurrent Analyst RatingsLatest ALPN, ACRS, and DMAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024ALPNAlpine Immune SciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/12/2024ALPNAlpine Immune SciencesSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$42.00 ➝ $65.004/11/2024ALPNAlpine Immune SciencesLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/11/2024ALPNAlpine Immune SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/11/2024ALPNAlpine Immune SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral4/11/2024ALPNAlpine Immune SciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $65.004/11/2024ALPNAlpine Immune SciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Sector Perform$41.00 ➝ $65.004/11/2024ALPNAlpine Immune SciencesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Peer Perform4/9/2024ALPNAlpine Immune SciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.003/21/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.003/21/2024DMACDiaMedica TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $6.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$31.25M2.77N/AN/A$2.22 per share0.55ALPNAlpine Immune Sciences$58.88M71.86N/AN/A$5.64 per share11.45DMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$88.48M-$1.27N/AN/AN/A-283.15%-64.56%-49.10%5/13/2024 (Estimated)ALPNAlpine Immune Sciences-$32.18M-$0.64N/AN/AN/A-54.66%-15.54%-11.34%5/9/2024 (Estimated)DMACDiaMedica Therapeutics-$19.38M-$0.62N/A∞N/AN/A-40.07%-37.90%5/20/2024 (Estimated)Latest ALPN, ACRS, and DMAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024N/ADMACDiaMedica Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A 3/18/2024Q4 2023ALPNAlpine Immune Sciences-$0.32$0.15+$0.47$0.15$6.90 million$30.85 million2/27/2024Q4 2023ACRSAclaris Therapeutics-$0.37-$0.30+$0.07-$0.58$3.96 million$17.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AALPNAlpine Immune SciencesN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.164.16ALPNAlpine Immune SciencesN/A7.867.86DMACDiaMedica TherapeuticsN/A19.2719.27OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ALPNAlpine Immune Sciences75.17%DMACDiaMedica Therapeutics10.12%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.50%ALPNAlpine Immune Sciences42.30%DMACDiaMedica Therapeutics7.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics8670.93 million67.02 millionOptionableALPNAlpine Immune Sciences14265.55 million37.82 millionOptionableDMACDiaMedica Therapeutics1837.96 million35.23 millionOptionableALPN, ACRS, and DMAC HeadlinesSourceHeadlineDiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunchzacks.com - April 18 at 11:10 AMDiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Strokebusinesswire.com - April 17 at 4:08 PMDiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Cornerzacks.com - April 15 at 10:36 AMDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 25 at 1:07 PMWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Richinvestorplace.com - March 23 at 6:00 AMDiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 22 at 6:49 PMDMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023investorplace.com - March 19 at 9:53 PMRecap: DiaMedica Therapeutics Q4 Earningsbenzinga.com - March 19 at 7:30 PMDiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Resultsbusinesswire.com - March 19 at 4:15 PMTryp Therapeutics Inc. (TRYP.CN)ca.finance.yahoo.com - March 6 at 4:00 PMDiaMedica Therapeutics Stock (NASDAQ:DMAC) Dividends: History, Yield and Datesbenzinga.com - February 9 at 8:39 PMDiaMedica Therapeutics Announces Poster Presentation at International Stroke Conferencefinance.yahoo.com - January 29 at 6:04 PMDiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 52% ownership, insiders own 37%finance.yahoo.com - January 7 at 10:04 AMHere's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situationfinance.yahoo.com - December 11 at 8:35 AMDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 15 at 3:10 PMAnalysts’ Top Healthcare Picks: Diamedica Therapeutics (DMAC), Abivax SA Sponsored ADR (ABVX)markets.businessinsider.com - November 14 at 11:48 PMQ3 2023 DiaMedica Therapeutics Inc Earnings Callfinance.yahoo.com - November 14 at 11:48 PMDiaMedica Therapeutics Inc. (DMAC) Reports Third Quarter 2023 Financial Resultsgurufocus.com - November 14 at 3:22 PMDiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$20.2mfinance.yahoo.com - November 14 at 8:38 AMDiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.01msn.com - November 13 at 7:14 PMDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 13 at 7:14 PMEarnings Outlook For DiaMedica Therapeuticsbenzinga.com - November 10 at 1:49 PMDiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023finance.yahoo.com - November 9 at 9:58 AMDiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023finance.yahoo.com - November 6 at 8:33 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAclaris TherapeuticsNASDAQ:ACRSAclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Alpine Immune SciencesNASDAQ:ALPNAlpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.DiaMedica TherapeuticsNASDAQ:DMACDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.